{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:13:25Z","timestamp":1791252805521,"version":"4.1.0"},"reference-count":83,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Systemic light chain (AL) amyloidosis is a rare clonal plasma cell disorder characterized by the production of amyloidogenic immunoglobulin light chains, which causes the formation and deposition of amyloid fibrils, leading to multi\u2010organ dysfunction. Current treatment is directed at the underlying plasma cell clone to achieve a profound reduction in the monoclonal free light chain production. The standard\u2010of\u2010care first\u2010line therapy is a combination of daratumumab, cyclophosphamide, bortezomib and dexamethasone (D\u2010VCd regimen), resulting in high rates of haematological and organ responses. However, AL amyloidosis remains incurable, and all patients inevitably relapse. Hence, novel treatment options are needed for patients with an inadequate response or relapsed\/refractory disease. B\u2010cell maturation antigen (BCMA) is a tumour necrosis factor (TNF\u00a0receptor superfamily receptor overexpressed on plasma cells in multiple myeloma (MM) and AL amyloidosis. Recently, several novel anti\u2010BCMA immunotherapies have been approved for the treatment of relapsed\/refractory MM, including antibody\u2013drug conjugate belantamab mafodotin, bispecific antibodies teclistamab and elranatamab and chimeric antigen receptor T\u2010cell therapies idecabtagene vicleucel and ciltacabtagene autoleucel. Despite lower expression than in MM, BCMA is also a promising target in AL amyloidosis. This review aims to provide up\u2010to\u2010date information on the efficacy and toxicity of anti\u2010BCMA therapy in AL amyloidosis.<\/jats:p>","DOI":"10.1111\/bjh.19960","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T05:14:12Z","timestamp":1735881252000},"page":"817-831","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Update on B\u2010cell maturation antigen\u2010directed therapies in <scp>AL<\/scp> amyloidosis"],"prefix":"10.1111","volume":"206","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7207-8534","authenticated-orcid":false,"given":"Krzysztof","family":"Jamroziak","sequence":"first","affiliation":[{"name":"Department of Hematology, Transplantation and Internal Medicine Medical University of Warsaw  Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8909-1145","authenticated-orcid":false,"given":"Klaudia","family":"Zielonka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Transplantation and Internal Medicine Medical University of Warsaw  Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4993-7828","authenticated-orcid":false,"given":"Jahanzaib","family":"Khwaja","sequence":"additional","affiliation":[{"name":"Department of Haematology University College London Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh D.","family":"Wechalekar","sequence":"additional","affiliation":[{"name":"Department of Haematology University College London Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"key":"e_1_2_15_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01274-X"},{"key":"e_1_2_15_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00529-w"},{"key":"e_1_2_15_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1917321"},{"key":"e_1_2_15_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2022.2093635"},{"key":"e_1_2_15_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004460"},{"key":"e_1_2_15_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2021.2002841"},{"key":"e_1_2_15_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.8499"},{"key":"e_1_2_15_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"e_1_2_15_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_2_15_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"e_1_2_15_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2043"},{"key":"e_1_2_15_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/10.11.1693"},{"key":"e_1_2_15_14_1","unstructured":"European Myeloma Network.A Phase 2 Study of Belantamab Mafodotin in Patients with Relapsed or Refractory AL Amyloidosis (EMN27) Identifier: NCT04617925 [Internet]. 2023 [cited 2023 Mar 14]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT04617925"},{"key":"e_1_2_15_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19286"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-185861"},{"key":"e_1_2_15_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000541594"},{"key":"e_1_2_15_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04890-z"},{"key":"e_1_2_15_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00950-3"},{"key":"e_1_2_15_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-189277"},{"key":"e_1_2_15_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-182971"},{"key":"e_1_2_15_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022937"},{"key":"e_1_2_15_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-186450"},{"key":"e_1_2_15_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14293"},{"key":"e_1_2_15_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30110697"},{"key":"e_1_2_15_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003783"},{"key":"e_1_2_15_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.772"},{"key":"e_1_2_15_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2422"},{"key":"e_1_2_15_29_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031330"},{"key":"e_1_2_15_30_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.1.129"},{"key":"e_1_2_15_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9822(00)00566-2"},{"key":"e_1_2_15_32_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.3.1322"},{"key":"e_1_2_15_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00962-7"},{"key":"e_1_2_15_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2527"},{"key":"e_1_2_15_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2017.03.077"},{"key":"e_1_2_15_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0637"},{"key":"e_1_2_15_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127332"},{"key":"e_1_2_15_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8333"},{"key":"e_1_2_15_39_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.150896"},{"key":"e_1_2_15_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00505-4"},{"key":"e_1_2_15_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09241.x"},{"key":"e_1_2_15_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126988"},{"key":"e_1_2_15_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25734"},{"key":"e_1_2_15_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00716-3"},{"key":"e_1_2_15_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00246-2"},{"key":"e_1_2_15_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-535088"},{"key":"e_1_2_15_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2289"},{"key":"e_1_2_15_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34987"},{"key":"e_1_2_15_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00717-2"},{"key":"e_1_2_15_50_1","unstructured":"AndersonL.A Dose\u2010Finding and Proof\u2010of\u2010Concept Phase 1\/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis Identifier: NCT05145816 [Internet]. 2024 [cited 2024 Feb 29]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05145816"},{"key":"e_1_2_15_51_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-CT067"},{"key":"e_1_2_15_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405090"},{"key":"e_1_2_15_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403407"},{"key":"e_1_2_15_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32909"},{"key":"e_1_2_15_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002393"},{"key":"e_1_2_15_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.69"},{"key":"e_1_2_15_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.8034"},{"issue":"1","key":"e_1_2_15_58_1","first-page":"501","article-title":"T cell engagement without cytokine storm: a novel Bcma x CD3 antibody killing myeloma cells with minimal cytokine secretion","volume":"130","author":"Buelow B","year":"2017","journal-title":"Blood"},{"key":"e_1_2_15_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110427"},{"key":"e_1_2_15_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159009"},{"key":"e_1_2_15_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01504"},{"key":"e_1_2_15_62_1","unstructured":"An Open\u2010Label Phase 1b Study Evaluating the Safety and Efficacy of ABBV\u2010383 in AL Amyloidosis Identifier: NCT06158854 [Internet]. 2023 [cited 2023 Dec 6]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT06158854"},{"key":"e_1_2_15_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8006"},{"key":"e_1_2_15_64_1","unstructured":"A Phase 1\/2 Study of Linvoseltamab in Patients With Relapsed or Refractory Systemic Light Chain Amyloidosis Identifier: NCT06292780 [Internet]. 2024 [cited 2024 Mar 5]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT06292780"},{"key":"e_1_2_15_65_1","unstructured":"Phase 1b Dose Expansion Study of NXC\u2010201 for the Treatment of Patients with Relapsed or Refractory AL Amyloidosis Identifier: NCT06097832 [Internet]. 2023 [cited 2023 Oct 24]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT06097832"},{"key":"e_1_2_15_66_1","unstructured":"Phase 1 First\u2010in\u2010Human Dose Escalation Study of JNJ\u201079635322 a Trispecific Antibody in Participants with Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis Identifier: NCT05652335 [Internet]. 2024 [cited 2024 Feb 28]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05652335"},{"key":"e_1_2_15_67_1","unstructured":"First\u2010in\u2010Human Open\u2010Label Phase 1\/2 Study to Investigate Safety and Efficacy of SAR445514 an NKcell Engager (NKCE) Targeting B\u2010cell Maturation Antigen (BCMA) in Monotherapy in Participants with Relapsed\/Refractory Multiple Myeloma (RRMM) and in Relapsed\/Refractory Light\u2010chain Amyloidosis (RRLCA) Identifier: NCT05839626 [Internet]. 2023 [cited 2023 Nov 18]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05839626"},{"key":"e_1_2_15_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174941"},{"key":"e_1_2_15_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"e_1_2_15_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-629071"},{"key":"e_1_2_15_71_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.280169"},{"key":"e_1_2_15_72_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_2_15_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_2_15_74_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0343-9"},{"key":"e_1_2_15_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.10.049"},{"key":"e_1_2_15_76_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226"},{"key":"e_1_2_15_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842"},{"key":"e_1_2_15_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16697"},{"key":"e_1_2_15_79_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2018.001"},{"key":"e_1_2_15_80_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0681-6"},{"key":"e_1_2_15_81_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281628"},{"key":"e_1_2_15_82_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.228577"},{"key":"e_1_2_15_83_1","unstructured":"deLarreaCFl.Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients with Relapsed\/Refractory Multiple Myeloma to Proteasome Inhibitors Immunomodulators and Anti\u2010CD38 Antibody. Identifier: NCT04309981 [Internet]. 2023 [cited 2023 Aug 23]. Available from:https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04309981"},{"key":"e_1_2_15_84_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202048953"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.19960","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T13:18:47Z","timestamp":1748351927000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.19960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":83,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1111\/bjh.19960"],"URL":"https:\/\/doi.org\/10.1111\/bjh.19960","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]},"assertion":[{"value":"2024-08-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}